Oak Associates Ltd. OH Grows Position in Stryker Co. (NYSE:SYK)

Oak Associates Ltd. OH grew its stake in Stryker Co. (NYSE:SYK) by 43.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,164 shares of the medical technology company’s stock after buying an additional 1,860 shares during the period. Oak Associates Ltd. OH’s holdings in Stryker were worth $2,219,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Morse Asset Management Inc grew its stake in Stryker by 16.5% during the 3rd quarter. Morse Asset Management Inc now owns 1,410 shares of the medical technology company’s stock valued at $509,000 after purchasing an additional 200 shares during the last quarter. Continuum Advisory LLC lifted its stake in Stryker by 310.8% during the 3rd quarter. Continuum Advisory LLC now owns 456 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 345 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Stryker in the 3rd quarter valued at $966,000. Toronto Dominion Bank raised its holdings in shares of Stryker by 2.3% during the third quarter. Toronto Dominion Bank now owns 173,965 shares of the medical technology company’s stock worth $62,847,000 after purchasing an additional 3,855 shares during the last quarter. Finally, Sunbelt Securities Inc. grew its position in Stryker by 25.6% during the 3rd quarter. Sunbelt Securities Inc. now owns 501 shares of the medical technology company’s stock worth $181,000 after purchasing an additional 102 shares during the period. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Down 4.4 %

Shares of SYK stock opened at $347.04 on Friday. The company has a 50-day moving average of $376.39 and a two-hundred day moving average of $373.61. The firm has a market cap of $132.46 billion, a PE ratio of 44.72, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the firm posted $3.46 earnings per share. On average, analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analyst Ratings Changes

SYK has been the subject of several analyst reports. The Goldman Sachs Group set a $422.00 price objective on Stryker in a report on Tuesday, March 4th. Wells Fargo & Company boosted their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Argus set a $450.00 price objective on shares of Stryker in a research note on Monday, February 3rd. Barclays boosted their target price on shares of Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Finally, Citigroup reaffirmed a “buy” rating and issued a $450.00 price objective on shares of Stryker in a report on Wednesday, February 26th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.